BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

magAssist's NyokAssist™️ granted Designation by the FDA as a Breakthrough Device

Interventional VADs have been proven as an effective clinical therapy to provide mechanical circulatory support for high-risk percutaneous interventions, t...

August 22, 2023 | News

Everest Medicines' Partner Calliditas Therapeutics Gets FDA Priority Review for Nefecon® in IgA Nephropathy

"We congratulate our partner Calliditas for being granted priority review by the FDA for full approval and taking a step closer to offering this first-in-d...

August 22, 2023 | Regulatory

Neurophth Begins Phase I/II Trial for Second Gene Therapy with First Patient Dosed

Neurophth is conducting a Phase I/II, multi-region, multi-center, single-arm, open-labeled, dose-finding study aimed at evaluating the safety, tole...

August 18, 2023 | News

Minghui Pharma Enrolls First Patient in Phase 3 Study for MH004 Cream in Atopic Dermatitis

The phase 3 clinical trial aims to evaluate the safety and efficacy of the investigational topical cream in a larger patient population. Leveraging the con...

August 18, 2023 | News

Novo Holdings Joins $290m Fundraising for Sangon Biotech

Based in China, and with close to 30 years in operation, Sangon Biotech is a leading provider of life science tools in China. The Company offers ...

August 18, 2023 | News

Innovent's SINTBILO® Receives NMPA Approval for Treating Hypercholesterolemia

The prevalence of cardiovascular diseases is continuously increasing in China, among which atherosclerotic cardiovascular disease (ASCVD) is the leadi...

August 17, 2023 | News

Infinitus & Jiangnan University Create Center for Herbal Medicine-Probiotic Combo

Lam Yu, CEO of Infinitus Global and Vice Chairman of Infinitus (China), expressed his enthusiasm in his speech, "Infinitus has been deeply involved in th...

August 16, 2023 | News

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

Kelun-Biotech's Phase III Trial of SKB264 Meets Endpoint in Advanced TNBC

Kelun-Biotech recently held an Independent Data Monitoring Committee (IDMC) meeting to review the interim analysis data of the Phase III clinical trial of ...

August 15, 2023 | News

Neurophth Raises Almost $95M for Gene Therapy Trials in Series C+ Funding

Additionally, several prominent investment firms participated, including CMG-SDIC Capital, Silicon Paradise Asset Management and Yangtze River Industry Fun...

August 14, 2023 | News

Asieris Reports Successful Phase III Bridging Trial for Hexvix® in Bladder Cancer Diagnosis

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

August 14, 2023 | News

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

Under the collaboration, Boostimmune will have access to WuXi Biologics' integrated discovery services and extensive expertise in antibody discovery, lead ...

August 11, 2023 | News

First Patient Dosed in Phase III Prostate Cancer Imaging Study of TLX591-CDx in China

The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...

August 11, 2023 | News

Positive Phase 3 Results for Fasedienol Nasal Spray in Social Anxiety Disorder by AffaMed's Partner Vistagen

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reducti...

August 11, 2023 | News

Stay Connected